Effect of dietary fat on oral bioavailability of tepoxalin in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 28, Issue 3, 2005, Pages 287-291

  Homer, L M ^a   Clarke, C R ^a   Weingarten, A J ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG METABOLITE; TEPOXALIN; ZUBRIN RAPIDLY DISINTEGRATING TABLET;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOG; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; FAT INTAKE; FEEDING; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMAL FEED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CROSS-OVER STUDIES; DIETARY FATS; DOGS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; PYRAZOLES;

CANIS FAMILIARIS;

EID: 21244481715     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2005.00644.x     Document Type: Article

References (11)

1. Argentieri, D.C., Ritchie, D.M., Ferro, M.P., Kirchner, T., Wachter, M.P., Anderson, D.W., Rosenthale, M.E. & Capetola, R.J. (1994) Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. The Journal of Pharmacology and Experimental Therapeutics, 271, 1399-1408.
2. Bourne, D.W.A. (1989) BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Computer Methods and Programs in Biomedicine, 29, 191-195.
3. Brown, R.D. & Manno, J.E. (1978) ESTRIP, a basic computer program for obtaining initial polyexponential parameter estimates. Journal of Pharmaceutical Sciences, 67, 1687-1691.
4. Connolly, P.J., Wetter, S.K., Beers, K.M. et al. (1999) N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorganic and Medicinal Chemistry Letters, 9, 979-984.
5. Humberstone, A.J., Porter, C.J. & Charman, W.N. (1996) A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Journal of Pharmaceutical Sciences, 85, 525-529.
6. Knight, E.V., Kimball, J.P., Keenan, C.M. et al. (1996) Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundamental and Applied Toxicology, 33, 38-48.
7. Mithani, S.D., Bakatselou, V., TenHoor, C.N. & Dressman, J.B. (1996) Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharmaceutical Research, 13, 163-167
8. Ogunbona FA, Smith IF & Olawoye OS. (1985) Fat contents of meals and bioavailability of griseofulvin in man. The Journal of Pharmacy and Pharmacology, 37, 283-284.
9. Porter, C.J. & Charman, W.N. (2001) Intestinal lymphatic drug transport: an update. Advanced Drug Delivery Reviews, 50, 61-80.
10. Riviere, J.E. (1999) Absorption. In Comparative Pharmacokinetics, Principles, Techniques, and Applications, 1st edn. pp, 21-46. Iowa State University Press, Ames, IA.
11. Willburger, R.E., Wittenberg, R.H., Schmidt, K., Kleemeyer, K.S. & Peskar, B.A. (1998) Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis. Acta Orthopaedica Scandinavica, 69, 295-300.